Pharming Group (NASDAQ:PHAR) Shares Gap Up – What’s Next?

Shares of Pharming Group (NASDAQ:PHAR) gapped up before the market opened on Friday . The stock had previously closed at $8.54, but opened at $9.06. Pharming Group shares last traded at $9.15, with a volume of 969 shares changing hands.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, December 17th. Jefferies Financial Group initiated coverage on Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 target price for the company.

Pharming Group Stock Performance

The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm’s fifty day moving average price is $9.36 and its 200 day moving average price is $8.52. The stock has a market capitalization of $592.89 million, a price-to-earnings ratio of -33.52 and a beta of -0.10.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.